Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC945 for fungal bronchitis in chronic respiratory disease
2018-000244-26Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary aspergillosis, Candida pneumonia and fungal bronchitis comparing PC945 inhalation with Placebo inhalation (2 arms). Primary endpoint: Mycological response in sputum culture at Visit 5. Started Apr 2018; status: terminated.
02
Drugs
opelconazole
03
Conditions
pulmonary aspergillosisCandida pneumoniafungal bronchitis
Beyond the preview
Go deeper on 2018-000244-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000244-26.